文献速递核素与放射性配体治疗骨显像与常规 SPECT

177Lu-DOTA-IBA治疗多发性骨转移疗效显著

Excellent Response to 177 Lu-DOTA-IBA Therapy of Patients With Multiple Skeletal Metastases.
PubMed 文献 · Clin Nucl Med · 2026-04-10

本研究纳入28例多发性骨转移患者,评估177Lu-DOTA-IBA治疗的安全性与疗效。结果显示仅1例(4%)出现新发3级贫血,79%(22/28)骨痛缓解,54%(15/28)经68Ga-DOTA-IBA PET/CT评估达部分缓解。提示该疗法安全有效,尤其利于疼痛控制和生活质量改善。

要点

  • 28例多发性骨转移患者接受177Lu-DOTA-IBA治疗,中位治疗周期为3。
  • 治疗后仅1例(4%)出现新发3级贫血,无严重不良事件。
  • 79%(22/28)骨痛缓解,54%(15/28)PET/CT示部分缓解。

核心结论

  • 177Lu-DOTA-IBA在多发性骨转移患者中未观察到严重不良事件,表现出良好的疗效,尤其对疼痛控制和生活质量改善有前景。

研究设计与样本

  • 纳入28例多发性骨转移患者,接受177Lu-DOTA-IBA治疗,监测血液生物标志物评估安全性,采用KPS、VAS疼痛评分及68Ga-DOTA-IBA PET/CT随访评估疗效。

主要发现

  • 28例患者中位治疗周期为3。
  • 25例(89%)基线血液学参数异常,治疗后血细胞计数与基线基本不变,仅1例(4%)出现新发3级贫血。
  • 骨痛缓解率为79%(22/28),68Ga-DOTA-IBA PET/CT随访显示15例(54%,15/28)达部分缓解。

关键数值与推荐

  • 骨痛缓解率79%(22/28),部分缓解率54%(15/28),新发3级贫血发生率4%(1/28)。

临床怎么用

  • 对于多发性骨转移患者,177Lu-DOTA-IBA可作为安全有效的治疗选择,尤其适用于疼痛控制和生活质量改善。

局限性

  • 样本量较小(28例),未设对照组,随访时间未报告,需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: DOTA-ibandronic acid (DOTA-IBA) is a recently developed prodrug targeting bone metastases. Labeling with 68 Ga/ 177 Lu ( 68 Ga/ 177 Lu-DOTA-IBA) induces good curative effects and safety in these patients. However, there has been no evaluation of the safety and effectiveness of 177 Lu-DOTA-IBA in cases of multiple bone metastases. Here, the hematological toxicity and efficacy of 177 Lu-DOTA-IBA in cases of multiple bone metastases were investigated. PARTICIPANTS AND METHODS: Twenty-eight cases of multiple bone metastases were enrolled in the analysis. Following 177 Lu-DOTA-IBA treatment, blood biomarkers were monitored to evaluate the safety of treatment. Karnofsky Performance Status assessments (KPS), Visual Analogue Scale (VAS) pain scores, and 68 Ga-DOTA-IBA PET/CT follow-up were utilized for evaluation of the curative effect. RESULTS: The 28 enrolled patients with multiple bone metastases had a median treatment cycle of 3. The baseline hematological parameters of 25 patients (89%) were abnormal. Post-treatment follow-up showed that blood counts remained essentially unchanged from baseline, with only one patient (4%) developed new grade 3 anemia. A 79% (22/28) rate of bone pain remission was observed and follow-up 68 Ga-DOTA-IBA PET/CT images showed that 15 cases (54%, 15/28) had partial remission. CONCLUSIONS: No serious adverse events were observed in patients with multiple bone metastases who received 177 Lu-DOTA-IBA. The therapeutic agent demonstrated promising efficacy, particularly for pain control and improved quality of life, suggesting that 177 Lu-DOTA-IBA is a safe, effective therapeutic option for this population.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hua Q, Wang Y, Pei W, et al. Excellent Response to 177 Lu-DOTA-IBA Therapy of Patients With Multiple Skeletal Metastases. Clin Nucl Med. 2026. PMID: 41984891. doi:10.1097/RLU.0000000000006475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。